The Technical Analyst
Annexon, Inc. [ANNX]
Exchange: Nasdaq Global Select Sector: Healthcare Industry: Biotechnology
Annexon, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
2.15% $3.32
Last updated: 16 May 2022 @ 10:15 am
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 128.03 mill |
| EPS: | -3.40 |
| P/E: | 0.000 |
| Earnings Date: | Aug 15, 2022 |
| SharesOutstanding: | 38.56 mill |
| Avg Daily Volume: | 0.600 mill |
| RATING 2022-05-13 |
|---|
| B |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$7.73 (132.90%) $4.41 |
| Date: 2022-05-16 |
| True Range Average |
|---|
|
+/- $0.295 ( +/- 9.08%) Range: 2.96 - 3.55 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-04-14 | Love Douglas | Buy | 60 000 | Common Stock |
| 2022-02-11 | Mattheakis Larry | Buy | 100 000 | Stock Option (Right to Buy) |
| 2022-02-11 | Mattheakis Larry | Buy | 12 500 | Common Stock |
| 2022-02-11 | Lew Jennifer | Buy | 100 000 | Stock Option (Right to Buy) |
| 2022-02-11 | Lew Jennifer | Buy | 12 500 | Common Stock |
| INSIDER POWER |
|---|
| 71.11 |
| Last 100 transactions |
| Buy: 2 094 196 | Sell: 341 408 |
Forecast:
11:52 - $3.26
Live Trading Signals (every 1 min)
Forecast
1: 10:22 - $3.32
Forecast 2: 11:12 - $3.26
Forecast 3: 11:52 - $3.26
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.32 (2.15% ) |
| Volume | 0.0423 mill |
| Avg. Vol. | 0.600 mill |
| % of Avg. Vol | 7.05 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ANNX
273 Signals | Accuracy: 16.85% | Accuracy Buy: 22.06% | Accuracy Sell: 11.68%
Avg return buy: -0.21 % | Avg return sell: 0.32 %
$1 invested is now $0.74 or -25.92% since 20-04-22
| Date | Signal | @ | Closed | % | May 16 - 10:07 | buy | $3.26 | N/A | Active |
|---|---|---|---|---|
| May 16 - 09:55 | sell | $3.25 | $3.26 @ May 16 - 10:06 | 0.31% |
| May 16 - 09:45 | buy | $3.29 | $3.26 @ May 16 - 09:54 | -0.91% |
| May 13 - 15:57 | sell | $3.26 | $3.30 @ May 16 - 09:44 | 1.23% |
| May 13 - 15:50 | buy | $3.28 | $3.26 @ May 13 - 15:56 | -0.61% |
| May 13 - 15:37 | sell | $3.26 | $3.27 @ May 13 - 15:49 | 0.31% |
| May 13 - 15:32 | buy | $3.29 | $3.26 @ May 13 - 15:36 | -0.91% |
| May 13 - 15:26 | sell | $3.25 | $3.26 @ May 13 - 15:31 | 0.31% |
| May 13 - 15:18 | buy | $3.28 | $3.25 @ May 13 - 15:24 | -0.91% |
| May 13 - 15:05 | sell | $3.24 | $3.28 @ May 13 - 15:17 | 1.23% |
ANNX
Latest Press Releases
2022-04-07 06:30:00 - Press Release
Annexon Biosciences Completes Enrollment In Archer Phase 2 Trial Of Novel C1q Inhibitor, Anx007, In Patients With Geographic Atrophy
Topline efficacy and safety data expected in first half of 2023 topline efficacy and safety data expected in first half of 2023
2022-04-04 06:30:00 - Press Release
Annexon Biosciences To Participate In The 21st Annual Needham Virtual Healthcare Conference
Cambridge, mass., april 04, 2022 (globe newswire) -- annexon, inc. (nasdaq: annx), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that douglas love, esq., president & chief executive officer, will participate in a fireside chat at the 21st annual needham virtual healthcare conference on monday, april 11, 2022 at 3:45 p.m. et.
2022-02-28 06:30:00 - Press Release
Annexon Biosciences To Participate In The Cowen 42nd Annual Healthcare Conference
Brisbane, calif., feb. 28, 2022 (globe newswire) -- annexon, inc. (nasdaq: annx), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, today announced that douglas love, esq., president and chief executive officer, will participate in a virtual panel titled, “orphan cns panel,” during the cowen 42nd annual healthcare conference on tuesday, march 8, 2022, at 2:10 p.m. et.
2022-01-20 06:30:00 - Press Release
Annexon Biosciences Appoints Bettina M. Cockroft, M.d.
Brisbane, calif., jan. 20, 2022 (globe newswire) -- annexon, inc. (“annexon”) (nasdaq: annx), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, today announced the appointment of biotech executive bettina m. cockroft, m.d., senior vice president and chief medical officer of sangamo therapeutics, inc., to the company's board of directors.
2022-01-04 16:05:00 - Press Release
Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement In Clinical Measures With Anx005 In Huntington's Disease Following Six-month Treatment
Anx005 has been generally well-tolerated and has shown full target engagement of c1q in the csf
Latest News
2022-05-05 06:30:00 - GlobeNewsWire
Annexon Biosciences to Participate in Upcoming May Investor Conferences
BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following May investor conferences:
2022-04-20 15:41:34 - PennyStocks
What Are Penny Stocks? What You Need to Know and 3 to Watch
Check these three penny stocks out for your watchlist The post What Are Penny Stocks? What You Need to Know and 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-03-03 16:01:00 - GlobeNewsWire
Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillain-Barré Syndrome and Huntington's Disease at AAN 2022
BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, today announced that the company will present preclinical data highlighting its approach of inhibiting C1q to address a number of complement-mediated diseases. The data are being presented in oral and poster sessions at the American Academy of Neurology (AAN) Annual meeting, being held in Seattle from April 2-7, 2022, and virtually from April 24-26, 2022.
2022-02-07 06:21:59 - Seeking Alpha
BMEZ: Buy Low, Hold For The Distribution And Rebound
2022-01-05 17:10:00 - The Motley Fool
Why Annexon Biosciences Stock Plummeted 34% Today
2022-01-05 11:19:59 - Pulse2
Annexon Stock (ANNX): Why The Price Substantially Dropped Today
The stock price of Annexon Inc (NASDAQ: ANNX) fell by over 35% during intraday trading today. This is why it happened.
2022-01-05 06:33:07 - Benzinga
Annexon's Interim Mid-Stage Results On Huntington's Disease Candidate Fails To Cheer
Annexon Inc (NASDAQ: ANNX) posted interim data from its ongoing Phase 2 trial of ANX005 in patients with Huntington's disease (HD) who completed the 24-week treatment period. Annexon is developing ANX005, its lead monoclonal antibody candidate, for a range of complement-mediated disorders, including HD.
2022-01-04 06:30:00 - GlobeNewsWire
Annexon Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, Esq., President & Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 3:45 p.m. ET.
2021-11-30 14:18:25 - Pulse2
Annexon (ANNX) Stock: $40 Price Target From H.C. Wainwright
The shares of Annexon Inc (NASDAQ: ANNX) have received a $40 price target from H.C. Wainwright.
2021-10-04 06:30:00 - GlobeNewsWire
Annexon Biosciences Further Strengthens Its Executive Leadership Team With Appointment of Ted Yednock, Ph.D., to Chief Innovation Officer and Appointment of Larry Mattheakis, Ph.D.
– Dr. Ted Yednock's appointment enhances Annexon's commitment to scientific innovation and pursuit of future programs –